bethanechol has been researched along with Scleroderma, Systemic in 3 studies
Bethanechol: A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.
bethanechol : The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
Excerpt | Relevance | Reference |
---|---|---|
"Patients with systemic sclerosis (SSc) have impairments in gastrointestinal smooth muscle function." | 1.38 | Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function. ( Cohen, S; Dimarino, AJ; Jimenez, SA; Mehendiratta, V; Mendoza, F; Rattan, S; Singh, J, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Singh, J | 2 |
Mehendiratta, V | 2 |
Del Galdo, F | 1 |
Jimenez, SA | 2 |
Cohen, S | 2 |
DiMarino, AJ | 2 |
Rattan, S | 2 |
Mendoza, F | 1 |
Rees, WD | 1 |
Leigh, RJ | 1 |
Christofides, ND | 1 |
Bloom, SR | 1 |
Turnberg, LA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Precision Medicine in Systemic Sclerosis Gastrointestinal Disease: Evaluating Imaging and Stool Biomarkers for Differentiating Disease Stages and Treatment Responses[NCT04630782] | 70 participants (Anticipated) | Observational | 2020-04-09 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
3 other studies available for bethanechol and Scleroderma, Systemic
Article | Year |
---|---|
Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Anal Canal; Animals; Autoantibodies; Benz | 2009 |
Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function.
Topics: Acetylcholine; Anal Canal; Animals; Autoantibodies; Bethanechol; Colon; Female; Humans; Immunoglobul | 2012 |
Interdigestive motor activity in patients with systemic sclerosis.
Topics: Adult; Bethanechol; Bethanechol Compounds; Duodenum; Fasting; Female; Gastrointestinal Motility; Hum | 1982 |